20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Farnesyltransferase (Ftase) was identified by gene-expression profiling and by preclinical evaluation in in vitro and in vivo mantle cell lymphoma (MCL) models as a rational therapeutic target in MCL, one of the most refractory B-cell lymphomas. We conducted a multicenter phase II study of a potent Ftase inhibitor, tipifarnib, in patients with relapsed or refractory MCL.

          Related collections

          Author and article information

          Journal
          Cancer Chemother. Pharmacol.
          Cancer chemotherapy and pharmacology
          Springer Nature America, Inc
          1432-0843
          0344-5704
          Mar 2010
          : 65
          : 4
          Affiliations
          [1 ] INSERM U836 Equipe 7, Faculte de Medecine, Universite Joseph Fourier, Grenoble, France.
          Article
          10.1007/s00280-009-1185-4
          19960345
          fbd97838-803b-4e6a-b851-8570becdd4f3
          History

          Comments

          Comment on this article